Unicycive Therapeutics, INC.
At a glance
EmployeesNot reported
In business since2016
HeadquartersMountain View, CA
US patents4
SAM.gov UEIH44GMFU7L5B5
CAGE code206V9
Incorporated inDE
- medicines
- kidney disease
- agile development process
- commercial therapies
- Oxylanthanum Carbonate
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
4 US patents granted 2022–2025, 4 of them in the five years to SEP 2025.
Pharmaceuticals 4
- Nicorandil derivativesUS 12,396,989 · granted AUG 26, 2025
- Nicorandil derivativesUS 12,377,082 · granted AUG 5, 2025
- Nicorandil derivativesUS 12,036,211 · granted JUL 16, 2024
- Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and useUS 11,406,663 · granted AUG 9, 2022
Granted to Unicycive Therapeutics, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Unicycive Therapeutics, INC. | Mountain View | CA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


